Biocon Boosts Biosimilars In Australia With Sandoz Partnership
Five-Year Exclusive Marketing Deal Will Cover Indian Firm’s Trastuzumab And Bevacizumab
Biocon Biologics is seeking to bolster its biosimilars business in Australia, recently integrated after being acquired from former owner Viatris, through a deal that will see Sandoz market its Ogivri and Abevmy versions of trastuzumab and bevacizumab.
